Abstract 164P
Background
Sarcopenia is the loss of skeletal muscle mass and function that occurs with advancing age and certain diseases. It is a complication and independent risk factor for chemotherapy toxicity and mortality in patients with liver cirrhosis and hepatocellular carcinoma. The aim of this study was to study the impact of sarcopenia on chemotherapy toxicity and survival among hepatocellular carcinoma patients who underwent chemotherapy.
Methods
A systematic review was performed according to PRISMA guidelines. A literature search was conducted by two independent reviewers on all studies that included sarcopenia in hepatocellular carcinoma patients who underwent chemotherapy using PubMed, PubMed central, and Google Scholar databases. Study included elderly population was excluded. Outcome of interest included chemotherapy toxicity and overall survival. Data synthesis and statistical analysis were carried out using Review Manager software.
Results
A total of 10 studies were eligible for meta-analysis including a total of 1203 hepatocellular carcinoma patients. All included studies were retrospective cohort. Meta-analysis revealed a significant association between sarcopenia and overall survival (HR 1.76; 95% CI 1.37 – 2.25; P < 0.001). Sarcopenia was also associated with incidence of chemotherapy toxicity (OR 2.84; 95% CI 1.35 – 5.96; P = 0.006), including hand-foot syndrome, diarrhea, hepatic encephalopathy and hypertension. The quality of study assessed with Newcastle Ottawa Scale (NOS) showed “poor” in only 2 included studies while the remaining 8 studies were graded as “good”.
Conclusions
Sarcopenia can give negative impact on chemotherapy toxicities and survival outcomes for hepatocellular carcinoma patients who underwent chemotherapy. Prospective studies with a uniform definition of sarcopenia and same chemotherapy regimen are still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session